We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...
Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...
Bearish flow noted in Biogen (BIIB) with 1,136 puts trading, or 1.1x expected. Most active are Apr-25 160 puts and 11/29 weekly 162.5 calls, ...
Zacks.com on MSN1d
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage StudyCassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline ...
Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...
The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...
The Nasdaq 100 index has jumped to a record high recently. We explain why the QQQ ETF could drop sharply soon.
DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...
Major depressive disorder (MDD), commonly referred to as depression, is a serious medical condition that affects a person's ...
Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...
Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...
Highlights:,Biogen Inc. (BIIB) has underperformed the broader market and key healthcare ETFs in recent years.,The company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback